Kashyap B. Patel, MD, says value of care is an important metric, but often people lose sight of what patients have to pay out of pocket, and how this affects them.
Many new treatments for cancer are helping to alleviate the burden for patients, but at the same time, the cost of care is increasingly recognized as a “toxicity” of treatment. With high out-of-pocket expense, “it becomes hard for patients to sustain an appropriate level of cancer care,” said Kashyap B. Patel, MD, a medical oncologist and Advisory Board member for The Center for Biosimilars®.
For example, when patients retire from work, they often do not have Medicare supplemental insurance—Medigap—to help with the cost of co-pays, coinsurance, and deductibles, he noted in a recent Axios-sponsored webinar discussion about biosimilars and the costs of cancer care. Patel is also CEO of Carolina Blood and Cancer Care Associates in Rock Hill, South Carolina.
Among Medicare beneficiaries, as many as 19% do not have secondary insurance, he said. “Their out-of-pocket costs could vary between $2500 to $15,000, which is almost as much as what some of them make in some regions, so the benefits of cancer care are not reaching the populations we need to serve most.”
Among patients who have commercial coverage, the coinsurance payment, which is what patients pay after they’ve met their deductible, may range from 6% to 20% of costs, depending on the plan, according to Patel. “The system is not designed to look after the ultimate beneficiary, which is the patient.”
That said, Patel’s cancer treatment center is among 126 practices nationwide that are participating in the Oncology Care Model, which is a CMS pilot program to reduce costs of cancer care while increasing the value and quality of treatment afforded to patients. More emphasis needs to be placed on reducing out-of-pocket cost so that patients can get the full benefit of available therapies without suffering financial toxicity, Patel said.
In the health care community, he said, that message may not have filtered in.
“I’m not saying that my colleagues are not really conscientious, but they have not been appropriately educated about the potential benefits of reducing the out-of-pocket costs, as well as total cost of care,” he said.
More thorough attempts to educate health care providers about biosimilars and the use of incentives to promote employment of these agents can achieve this aim, Patel said. Such incentives were described in a separate portion of the Axios discussion that featured Rep Kurt Schrader, D-Oregon, who discussed a bill that would increase physician reimbursements for prescribing biosimilars.
Patel said that in his oncology practice biosimilars help him to save 35% on the cost of biologics, and for the population of Medicare beneficiaries he serves who do not have supplemental insurance, that savings could trim as much as $10,000 off their out-of-pocket costs of care.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.